Top Markets
Coin of the day
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

NBSE
주식 순위 #39173
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics,... Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.
주가
$0.378
마지막 동기화: 2024-05-24
시가총액
$618.41K
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 NeuBase Therapeutics, Inc. (NBSE)

카테고리

NeuBase Therapeutics, Inc. (NBSE)의 주식 분할 이력
NeuBase Therapeutics, Inc. 주식 (심볼: NBSE)은 총 0회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Aug 14, 2026에 발생했습니다.
Aug 14, 2026 이전에 매수한 NBSE 주식 1주는 현재 0주의 NBSE 주식에 해당합니다.
주식 분할 목록
연도 주식 분할 배수 누적 배수
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 주식 분할
회사 주식 분할 횟수 누적 배수 국가
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE